Evidence map›Paper›PMID 7984424›Full record

ArticleNucleic acids research1994

Rev of human immunodeficiency virus and Rex of the human T-cell leukemia virus type I can counteract an mRNA downregulatory element of the transferrin receptor mRNA.

A S Zolotukhin, J B Harford, B K Felber

Open access · bronzeAbstract read
In one paragraph

Article in Nucleic acids research, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trimethylguanosine capping selectively promotes expression of Rev-dependent HIV-1 RNAs.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

A S ZolotukhinHuman Retrovirus Pathogenesis Group, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702-1201.
J B Harford
B K Felber
National Cancer Institute · USNational Institutes of Health · US

Funding

PROVIDE BASIC CANCER RESEARCHN01CO074101 · CO · ADVANCED BIOSCIENCE LABORATORIES, INC. · PI VANDE WOUDE, GEORGE F · 1987 to 1994
–
NCI NIH HHS N0-CO-74101
6 · The paper itself

Abstract

Expression of the structural proteins of the human immunodeficiency virus type 1 (HIV-1), the human T-cell leukemia virus type I (HTLV-I), and of the transferrin receptor (TfR) mRNA depends on posttranscriptional regulatory mechanisms involving both positive and negative elements. In these systems the presence of elements decreasing mRNA expression have been demonstrated. The regulatory proteins (Rev, Rex or iron response element binding protein IRE-BP) antagonize the effects of the downregulatory elements by interacting directly with specific mRNA sites (Rev responsive element, RRE, Rex responsive element, RXRE, or iron responsive elements, IREs) resulting in stabilization and efficient expression of the corresponding mRNAs. To investigate whether this strategy involves common pathways of mRNA utilization, we have studied expression from hybrid mRNAs that contained these previously identified HIV-1 or TfR instability determinants and the binding sites of the regulatory proteins Rev, Rex and/or IRE-BP. Our results demonstrate that only low levels of these hybrid mRNAs accumulate in the absence of the positive regulatory factors Rev, Rex or IRE-BP. The presence of these factors counteracts the effect of heterologous downregulatory elements resulting in increased accumulation of the hybrid mRNAs. However, while Rev or Rex regulation also resulted in efficient protein expression, the IRE-BP only affected mRNA levels without significantly affecting protein expression, suggesting that the pathways of mRNA stabilization/expression are different in these systems.

Indexed as

DeferoxamineDown-RegulationGene Expression Regulation, ViralGene Products, gagGene Products, revGene Products, rexGene Products, tatHeLa CellsHeminHIV-1HumansHuman T-lymphotropic virus 1Iron-Regulatory ProteinsReceptors, TransferrinRegulatory Sequences, Nucleic Acidrev Gene Products, Human Immunodeficiency VirusDeferoxamineGene Products, gagGene Products, revGene Products, rexGene Products, tatHeminIron-Regulatory ProteinsReceptors, Transferrinrev Gene Products, Human Immunodeficiency VirusRNA-Binding ProteinsRNA, MessengerRNA, Viraltat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID7984424
PMCPMC308524
OpenAlexW2073775361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.